Literature DB >> 448186

Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis.

E A Ottesen, P F Weller.   

Abstract

Eosinophilia is frequently observed after treatment of patients with infections due to parasitic helminths. For definition of the characteristics and causes of post-treatment eosinophilic responses, 47 patients with Bancroft's filariasis, who were treated with diethylcarbamazine, and eight patients with schistosomiasis mansoni, who were treated with niridazole, were studied. After therapy for eight days, both groups developed significant (P less than 0.05) increases in their levels of eosinophilia, which peaked in two to four weeks. Maximal levels averaged two and one-half to three time the levels before treatment. Before therapy the number of circulating eosinophils was unrelated to intensity of infection in both groups, but after treatment, when the same relationship was examined in the larger group (the patients with filariasis), the degree of post-treatment eosinophilia was significantly correlated with the patients' worm burdens before treatment (r = 0.727; P less than 0.001). Thus, treatment of helminthic infections can provide a unique opportunity for studying eosinophil responses of humans to graded doses of antigen and has shown that acute responses are determined quantitatively by the amount of antigen initially presented to the host.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448186     DOI: 10.1093/infdis/139.3.343

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel.

Authors:  Claus M Reimert; Colin M Fitzsimmons; Sarah Joseph; Joseph K Mwatha; Frances M Jones; Gachuhi Kimani; Karl F Hoffmann; Mark Booth; Narcis B Kabatereine; David W Dunne; Birgitte J Vennervald
Journal:  Clin Vaccine Immunol       Date:  2006-05

Review 2.  The human eosinophil: roles in host defense and tissue injury.

Authors:  P F Weller; E J Goetzl
Journal:  Am J Pathol       Date:  1980-09       Impact factor: 4.307

Review 3.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

4.  Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.

Authors:  R Gopinath; L E Hanna; V Kumaraswami; V Perumal; V Kavitha; V Vijayasekaran; T B Nutman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

Review 5.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.

Authors:  A P Limaye; J S Abrams; J E Silver; K Awadzi; H F Francis; E A Ottesen; T B Nutman
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Therapy and Prevention for Human Toxocariasis.

Authors:  Jean-François Magnaval; Emilie Bouhsira; Judith Fillaux
Journal:  Microorganisms       Date:  2022-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.